Edgewise Therapeutics, Inc.

What they do

Edgewise built a muscle-focused small molecule discovery platform and has advanced oral precision medicines in skeletal and cardiac muscle. Its former lead asset, sevasemten, was an oral fast myofiber myosin inhibitor for Duchenne and Becker muscular dystrophy, and it was sold to Servier along with the muscular dystrophy business. The remaining pipeline is led by EDG-7500, an oral cardiac sarcomere modulator in a Phase 2 trial for obstructive and nonobstructive hypertrophic cardiomyopathy, and EDG-15400, in Phase 1 for a future heart failure with preserved ejection fraction target. The company has no approved products and has not generated revenue.

Revenue drivers

• Product sales — None. Edgewise has not generated any revenue to date and has no products approved for commercial sale.
• Sevasemten divestiture proceeds — In July 2026 Edgewise completed the sale of sevasemten and its muscular dystrophy program to Servier for $1,550 million in upfront cash plus up to $1,100 million in regulatory and commercial milestones, up to $2,650 million aggregate.
• EDG-7500 (hypertrophic cardiomyopathy) — Lead cardiovascular asset, currently in a multipart Phase 2 trial in obstructive and nonobstructive HCM; a Phase 3 program is targeted to start in the fourth quarter of 2026.
• EDG-15400 (HFpEF) — Second cardiac sarcomere modulator; it completed dosing in a Phase 1 healthy-volunteer trial and a Phase 2 trial in HFpEF is expected in the second half of 2026.

Recent performance

For the second quarter of 2026, Edgewise reported a net loss of $57.3 million, or $0.53 per share. R&D expenses were $47.5 million versus $33.6 million in the prior-year quarter, and G&A expenses were $14.4 million versus $9.1 million. Net losses were $57.3 million and $106.3 million for the three and six months ended June 30, 2026, compared with $36.1 million and $76.9 million in the same 2025 periods. Cash, cash equivalents and marketable securities were approximately $460.7 million at June 30, 2026, which excludes the $1,550.0 million in upfront Servier cash received July 10, 2026; pro forma for that receipt, the company cited $2,010.7 million before taxes and transaction costs. The company also announced positive top-line 12-week Phase 2 CIRRUS-HCM data for EDG-7500 in obstructive and nonobstructive HCM.

Strategy

Following the July 2026 closing of the Servier transaction, Edgewise is positioned as a cardiovascular-focused late-stage clinical company. Its stated priority is advancing EDG-7500 toward a Phase 3 program in HCM targeted to begin in the fourth quarter of 2026, based on the Phase 2 CIRRUS-HCM results. It also plans to move EDG-15400 into a Phase 2 trial in HFpEF in the second half of 2026 and to continue preclinical work on cardiovascular and cardiometabolic targets, including EDG-003. Management says the $1,550 million upfront proceeds strengthen the balance sheet and financial flexibility.

Risks

• No revenue and continuing losses — Edgewise has not generated any revenue, has an accumulated deficit of $652.7 million as of June 30, 2026, and expects to continue incurring significant losses.
• Clinical and regulatory failure — EDG-7500 and EDG-15400 remain unapproved, and positive Phase 2 HCM data do not guarantee that the planned Phase 3 trial or later regulatory review will succeed.
• Additional capital needs — The company states it will require substantial additional capital to finance operations, and raising it may dilute stockholders or restrict operations.
• Pipeline concentration after divestiture — After selling sevasemten and the muscular dystrophy business to Servier, Edgewise's prospects rest on a smaller cardiovascular pipeline now led by EDG-7500.

Outlook

Management expects to initiate a Phase 3 trial of EDG-7500 in HCM in the fourth quarter of 2026 and a Phase 2 trial of EDG-15400 in HFpEF in the second half of 2026. It states that existing cash and marketable securities of $460.7 million plus the $1,550 million upfront Servier proceeds will fund planned operating expenses and capital expenditures through at least the next 12 months. The company continues preclinical discovery work on additional cardiovascular and cardiometabolic targets.